Figure 2
From: M6P/IGF2Rloss of heterozygosity in head and neck cancer associated with poor patient prognosis
Kaplan-Meier estimates of relapse-free survival in patients with head and neck cancer. Tumors treated with radiotherapy alone (solid lines) were either mutated (RT, LOH) or unmutated (RT, non LOH) at the M6P/IGF2R locus. Tumors treated with combined modality therapy (dashed lines) were also either mutated (CM, LOH) or unmutated (CM, non LOH) at the M6P/IGF2R locus. Patient number (n), patients that failed (parentheses), censored patients (angled bars), and median follow-up times are provided for each patient group. RT, radiotherapy; CM, combined modality therapy; LOH, loss of heterozygosity.